Levodopa

# Levodopa ## Overview - **Classification**: Dopaminergic agent, precursor to dopamine. Typically co-administered with a peripheral decarboxylase inhibitor (carbidopa). - **Mechanism**: Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, replenishing dopamine levels in the substantia nigra. Carbidopa prevents peripheral conversion of levodopa, increasing central nervous system availability and reducing peripheral side effects. ## Primary Indications 1. **Parkinson's Disease (PD)**: Treatment of signs and symptoms of idiopathic Parkinson's disease. 2. **Postencephalitic Parkinsonism**: Parkinsonism following encephalitis. 3. **Symptomatic Parkinsonism**: Due to carbon monoxide or manganese intoxication. ## Adult Dosing (Carbidopa/Levodopa combination products are assumed, as levodopa alone is rarely used) ### Standard Dosing **Parkinson's Disease (Initial)** - **Dose**: **25 mg carbidopa / 100 mg levodopa** oral, 3 times daily. - **Frequency**: Three times daily. - **Route**: Oral. - **Titration**: Increase gradually by **25 mg/100 mg** daily or every other day, as tolerated, to **100 mg/1000 mg** daily. - **Maximum**: Typically **200 mg carbidopa / 2000 mg levodopa** per day. **Parkinson's Disease (Maintenance)** - **Dose**: Individualized, typically **25 mg/100 mg** to **50 mg/200 mg** per dose. - **Frequency**: Three to four times daily, or as needed for symptom control. - **Route**: Oral. - **Maximum**: **200 mg carbidopa / 2000 mg levodopa** per day (some forms may allow up to 2400 mg). ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment generally recommended; use with caution. - **Hepatic Impairment**: No specific dose adjustment generally recommended; use with caution. - **Elderly Patients**: Start with lower doses and titrate slowly due to increased sensitivity and potential for adverse effects. ## Pediatric Dosing **Note**: Levodopa is **not indicated for children under 18 years old** for Parkinson's disease. It is used off-label for certain pediatric dystonias (e.g., Dopa-Responsive Dystonia - DRD). All pediatric dosing below refers to **off-label use for DRD**. ### Neonates (0-28 days) - **Dose**: Not generally recommended; very limited data for this age group. - **Special Notes**: Use only in exceptional, severe cases under specialist guidance for specific conditions (e.g., severe DRD). ### Infants (1-12 months) - **Indication (Off-label)**: Dopa-Responsive Dystonia (DRD). - **Dose**: Initial: **0.5-1 mg/kg/day** levodopa equivalent, divided into 3-4 doses. - **Frequency**: 3-4 times daily. - **Titration**: Increase gradually by **0.5-1 mg/kg/day** every 3-7 days based on response. - **Maximum**: Generally up to **5-10 mg/kg/day** for initial management. - **Special Notes**: Monitor closely for dyskinesias, GI upset, and sleep disturbances. ### Children (1-12 years) - **Indication (Off-label)**: Dopa-Responsive Dystonia (DRD). - **Dose**: Initial: **1 mg/kg/day** levodopa equivalent, divided into 3-4 doses. - **Frequency**: 3-4 times daily. - **Titration**: Increase gradually by **1 mg/kg/day** every 3-7 days based on response. - **Maximum**: Up to **15-20 mg/kg/day** levodopa equivalent, or **800 mg/day**, whichever is less. - **Special Notes**: Use immediate-release formulations. Administer with carbidopa to reduce side effects. ### Adolescents (13-18 years) - **Indication (Off-label)**: Dopa-Responsive Dystonia (DRD). - **Dose**: Initial: **1 mg/kg/day** levodopa equivalent, divided into 3-4 doses. - **Frequency**: 3-4 times daily. - **Titration**: Increase gradually as needed based on response and tolerability. - **Maximum**: Up to **20 mg/kg/day** levodopa equivalent or **800 mg/day**, whichever is less. - **Special Notes**: Parkinson's Disease in this age group is rare; treatment should be managed by a neurologist. ## Safety Information ### Contraindications - **Absolute**: Narrow-angle glaucoma. - **Absolute**: Concomitant use with non-selective monoamine oxidase (MAO) inhibitors (within 2 weeks). - **Absolute**: Undiagnosed skin lesions or a history of melanoma. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting, dyskinesia, orthostatic hypotension, dizziness. - **Common (1-10%)**: Dry mouth, somnolence, confusion, hallucinations, vivid dreams. - **Serious but Rare**: GI hemorrhage, suicidal ideation, impulse control disorders (e.g., gambling), neuroleptic malignant syndrome (upon abrupt withdrawal). ### Key Drug Interactions - **Non-selective MAO Inhibitors**: Risk of hypertensive crisis; avoid concomitant use, separate by 2 weeks. - **Iron Salts**: May reduce levodopa absorption; separate administration by at least 2 hours. - **Antipsychotics (Dopamine Antagonists)**: May reduce the therapeutic effect of levodopa. - **High Protein Meals**: May reduce levodopa absorption and efficacy; advise taking on empty stomach. - **Pyridoxine (Vitamin B6)**: Large doses may reverse levodopa's effects if carbidopa is not co-administered. ## Monitoring & Follow-up - **Before Treatment**: Baseline blood pressure (including orthostatic), renal/hepatic function (if clinically indicated), mental status. - **During Treatment**: Monitor blood pressure (especially orthostatic), motor function (dyskinesia, "wearing off"), psychiatric status (hallucinations, confusion, impulse control disorders). - **Clinical Signs**: Watch for dyskinesias, "wearing off" periods, "on-off" phenomena, and changes in mood or behavior. ## Clinical Pearls - 💡 **Tip 1**: Administer carbidopa/levodopa on an empty stomach (30 min before or 1-2 hours after meals) for optimal absorption. - 💡 **Tip 2**: If nausea occurs, try taking with a small, non-protein snack or titrate the dose more slowly. - 💡 **Tip 3**: Counsel patients on potential for sudden sleep attacks and impulse control disorders (e.g., pathological gambling, hypersexuality). - 💡 **Tip 4**: Abrupt discontinuation can lead to a syndrome resembling Neuroleptic Malignant Syndrome; taper slowly if discontinuing. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.